Nonetheless, our model could easily explain why MLL fusion leukemias are sensitive to BET inhibitors44,45 and CDK4/6 inhibitors36,46, as BRD4 is a component of the mitotic bookmarking machinery47 and CDK4/6 inhibition halts G1/S progression48, respectively. This evidence concerns the gene CDK4 and leukemia.